J-Y Blay

Summary

Affiliation: place d'Arsonval
Country: France

Publications

  1. ncbi Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
  2. doi Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
    J Y Blay
    Ann Oncol 19:821-2. 2008
  3. ncbi [Optimizing current drugs]
    J Y Blay
    Unité Inserm 590, Centre Léon Bérard F69008 Lyon, France Hôpital Edouard Herriot, Place d Arsonval, F69003 Lyon, France
    Ann Pharm Fr 63:17-24. 2005
  4. ncbi [Anti-angiogenetic agents for solid tumors]
    J Y Blay
    Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Rev Med Interne 28:S7-8. 2007
  5. ncbi [Recommendations for the management of GIST patients]
    Jean Yves Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon
    Bull Cancer 92:907-18. 2005
  6. ncbi Targeted cancer therapies
    Jean Yves Blay
    INSERM Unit 590, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Bull Cancer 92:E13-8. 2005
  7. ncbi Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    J Y Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon and Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Ann Oncol 16:566-78. 2005
  8. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
  9. ncbi Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Ann Oncol 15:307-15. 2004
  10. pmc Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    T Bachelot
    Unité Cytokine et Cancer, INSERM U 453 and Centre Léon Bérard, 28 rue Laënnec 69008 Lyon, France
    Br J Cancer 88:1721-6. 2003

Detail Information

Publications15

  1. ncbi Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
    ..They are composed of a connective tissue stroma and epithelial elements. Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern...
  2. doi Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
    J Y Blay
    Ann Oncol 19:821-2. 2008
  3. ncbi [Optimizing current drugs]
    J Y Blay
    Unité Inserm 590, Centre Léon Bérard F69008 Lyon, France Hôpital Edouard Herriot, Place d Arsonval, F69003 Lyon, France
    Ann Pharm Fr 63:17-24. 2005
  4. ncbi [Anti-angiogenetic agents for solid tumors]
    J Y Blay
    Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Rev Med Interne 28:S7-8. 2007
  5. ncbi [Recommendations for the management of GIST patients]
    Jean Yves Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon
    Bull Cancer 92:907-18. 2005
    ..A national consensus meeting was therefore organized in order to identify the optimal management procedures for patients with GIST in localized and advanced stages...
  6. ncbi Targeted cancer therapies
    Jean Yves Blay
    INSERM Unit 590, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Bull Cancer 92:E13-8. 2005
    ..The present paper reviews examples of targeted cancer therapies and their results...
  7. ncbi Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    J Y Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon and Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Ann Oncol 16:566-78. 2005
    ..The objectives of this international consensus meeting were to describe the optimal management procedures for patients with GIST in localized and advanced stages, as well as research issues for the future...
  8. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
    ..This could have important therapeutic implications with regard to endostatin therapy and raises the question of a possible role of this humoral reaction against endostatin in the neoplastic process...
  9. ncbi Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Ann Oncol 15:307-15. 2004
    ..The primary management of adult soft tissue sarcomas (STS) is characterized by heterogeneity across centers. Several studies suggest that it is improved when coordinated by specialized sarcoma centers...
  10. pmc Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    T Bachelot
    Unité Cytokine et Cancer, INSERM U 453 and Centre Léon Bérard, 28 rue Laënnec 69008 Lyon, France
    Br J Cancer 88:1721-6. 2003
    ..Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients...
  11. ncbi Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma
    J Verweij
    Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 39:2006-11. 2003
    ..Imatinib mesylate is well tolerated at a dose of 400 mg bid. This dose is active in patients with KIT-positive GIST, but patients with other STS subtypes unselected for a molecular target are unlikely to benefit...
  12. doi Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  13. doi Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008
  14. ncbi [Chemotherapy of sarcomas: optimization of existing drugs and new molecules]
    J Fayette
    Service d Oncologie Medicale, Pavillon E, Hopital Edouard Herriot, Lyon, France
    Cancer Radiother 10:72-7. 2006
    ..Target therapies and antiangiogenic treatment have also begun to show results. It is advisable from now on to distinguish the different sub-type of sarcomas in order to assess cytotoxic activity...